Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia
|ClinicalTrials.gov Identifier: NCT00003933|
Recruitment Status : Completed
First Posted : May 2, 2003
Last Update Posted : August 7, 2014
RATIONALE: Diagnostic procedures, such as genetic testing, may improve the ability to detect acute lymphocytic leukemia and determine the extent of disease.
PURPOSE: Diagnostic study to try to detect changes in the genes of children who have been treated for relapsed acute lymphocytic leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Other: laboratory biomarker analysis|
- Determine the incidence of p16/p15 homozygous deletions and p15 promoter hypermethylation in acute lymphocytic leukemia cells of children treated on protocol CCG-1941.
- Determine the prognostic importance of p16/p15 abnormalities in these children.
- Determine the presence or absence of p16/p15 abnormalities in the dominant clone at diagnosis if present at relapse in these patients.
OUTLINE: Frozen cells are obtained from samples collected on protocol CCG-1941. DNA is isolated and examined using Southern blot analysis to assay for deletions and promoter hypermethylation of p16 and/or p15.
PROJECTED ACCRUAL: Approximately 100 samples will be obtained for this study.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||The Incidence and Prognostic Significance of P16 INK4A/ P15 INK4B Gene Alterations in Children With Relapsed ALL Treated on CCG-1941|
|Study Start Date :||April 1999|
|Primary Completion Date :||April 2006|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00003933
Show 41 Study Locations
|Study Chair:||Stephen P. Hunger, MD||University of Florida|